Hamza Achit1, Marc Soudant2, Kossar Hosseini2, Aurélie Bannay2, Jonathan Epstein2, Serge Bracard2, Francis Guillemin2. 1. From the Department of Clinical Epidemiology, INSERM CIC-EC 1433 (H.A., M.S., K.H., J.E.), Department of Medical Information (A.B.), and Department of Diagnostic and Interventional Neuroradiology, INSERM U 947 (S.B.), University Hospital of Nancy, France; and Department of Clinical Epidemiology, INSERM CIC-EC 1433, EA 4360 APEMAC, University of Lorraine and University Hospital of Nancy, France (F.G.). h.achit@chru-nancy.fr. 2. From the Department of Clinical Epidemiology, INSERM CIC-EC 1433 (H.A., M.S., K.H., J.E.), Department of Medical Information (A.B.), and Department of Diagnostic and Interventional Neuroradiology, INSERM U 947 (S.B.), University Hospital of Nancy, France; and Department of Clinical Epidemiology, INSERM CIC-EC 1433, EA 4360 APEMAC, University of Lorraine and University Hospital of Nancy, France (F.G.).
Abstract
BACKGROUND AND PURPOSE: The benefit of mechanical thrombectomy added to intravenous thrombolysis (IVT) in patients with acute ischemic stroke has been largely demonstrated. However, evidence of the economic incentive of this strategy is still limited, especially in the context of a randomized controlled trial. We aimed to analyze whether mechanical thrombectomy combined with IVT (IVMT) is cost-effective when compared with IVT alone. METHODS: Individual-level cost and outcome data were collected in the THRACE randomized controlled trial (Thrombectomie des Artères Cerébrales) including patients with acute ischemic stroke. Patients were assigned to receive IVT or IVMT. The primary outcomes were modified Rankin Scale score of functional independence at 90 days (score 0-2) and the EuroQol-5D quality-of-life score at 1 year. RESULTS: Treating acute ischemic stroke with IVMT (n=200) versus IVT (n=202) increased the rate of functional independence by 10.9% (53.0% versus 42.1%; P=0.028), at an increased cost of $2116 (€1909), with no significant difference in mortality (12% versus 13%; P=0.70) or symptomatic intracranial hemorrhage (2% versus 2%; P=0.71). The cost per one averted case of disability was estimated at $19 379 (€17 480). The incremental cost per one quality-adjusted life year gained was $14 881 (€13 423). On sensitivity analysis, the probability of cost-effectiveness with IVMT was 84.1% in terms of cases of averted disability and 92.2% in terms of quality-adjusted life years. CONCLUSIONS: Based on randomized trial data, this study demonstrates that IVMT used to treat acute ischemic stroke is cost-effective when compared with IVT alone. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01062698.
RCT Entities:
BACKGROUND AND PURPOSE: The benefit of mechanical thrombectomy added to intravenous thrombolysis (IVT) in patients with acute ischemic stroke has been largely demonstrated. However, evidence of the economic incentive of this strategy is still limited, especially in the context of a randomized controlled trial. We aimed to analyze whether mechanical thrombectomy combined with IVT (IVMT) is cost-effective when compared with IVT alone. METHODS: Individual-level cost and outcome data were collected in the THRACE randomized controlled trial (Thrombectomie des Artères Cerébrales) including patients with acute ischemic stroke. Patients were assigned to receive IVT or IVMT. The primary outcomes were modified Rankin Scale score of functional independence at 90 days (score 0-2) and the EuroQol-5D quality-of-life score at 1 year. RESULTS: Treating acute ischemic stroke with IVMT (n=200) versus IVT (n=202) increased the rate of functional independence by 10.9% (53.0% versus 42.1%; P=0.028), at an increased cost of $2116 (€1909), with no significant difference in mortality (12% versus 13%; P=0.70) or symptomatic intracranial hemorrhage (2% versus 2%; P=0.71). The cost per one averted case of disability was estimated at $19 379 (€17 480). The incremental cost per one quality-adjusted life year gained was $14 881 (€13 423). On sensitivity analysis, the probability of cost-effectiveness with IVMT was 84.1% in terms of cases of averted disability and 92.2% in terms of quality-adjusted life years. CONCLUSIONS: Based on randomized trial data, this study demonstrates that IVMT used to treat acute ischemic stroke is cost-effective when compared with IVT alone. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01062698.
Authors: Silke Walter; Iris Q Grunwald; Stefan A Helwig; Andreas Ragoschke-Schumm; Michael Kettner; Mathias Fousse; Martin Lesmeister; Klaus Fassbender Journal: Curr Atheroscler Rep Date: 2018-08-29 Impact factor: 5.113
Authors: Johanna Maria Ospel; Ryan McTaggart; Nima Kashani; Marios Psychogios; Mohammed Almekhlafi; Mayank Goyal Journal: Semin Intervent Radiol Date: 2020-05-14 Impact factor: 1.513
Authors: Bruce C V Campbell; Peter J Mitchell; Leonid Churilov; Mahsa Keshtkaran; Keun-Sik Hong; Timothy J Kleinig; Helen M Dewey; Nawaf Yassi; Bernard Yan; Richard J Dowling; Mark W Parsons; Teddy Y Wu; Mark Brooks; Marion A Simpson; Ferdinand Miteff; Christopher R Levi; Martin Krause; Timothy J Harrington; Kenneth C Faulder; Brendan S Steinfort; Timothy Ang; Rebecca Scroop; P Alan Barber; Ben McGuinness; Tissa Wijeratne; Thanh G Phan; Winston Chong; Ronil V Chandra; Christopher F Bladin; Henry Rice; Laetitia de Villiers; Henry Ma; Patricia M Desmond; Atte Meretoja; Dominique A Cadilhac; Geoffrey A Donnan; Stephen M Davis Journal: Front Neurol Date: 2017-12-14 Impact factor: 4.003
Authors: R Raj; S Bendel; M Reinikainen; S Hoppu; R Laitio; T Ala-Kokko; S Curtze; M B Skrifvars Journal: Crit Care Date: 2018-09-20 Impact factor: 9.097
Authors: Lan Gao; Andrew Bivard; Mark Parsons; Neil J Spratt; Christopher Levi; Kenneth Butcher; Timothy Kleinig; Bernard Yan; Qiang Dong; Xin Cheng; Min Lou; Congguo Yin; Chushuang Chen; Peng Wang; Longting Lin; Philip Choi; Ferdinand Miteff; Marj Moodie Journal: Front Neurol Date: 2021-12-14 Impact factor: 4.003
Authors: Ashlee Wheaton; Patrick T Fok; Jessalyn K Holodinsky; Peter Vanberkel; David Volders; Noreen Kamal Journal: Front Neurol Date: 2021-12-17 Impact factor: 4.003